Ying Xue
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ying Xue has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Chen Jiang
Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA
1 shared publication - Hongyi Zou
Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA 15213, USA
1 shared publication - Junnan Qi
Department of Pharmaceutical Sciences and Computational Chemical Genomics Screening Center, Pharmacometrics & Systems Pharmacology (PSP) PharmacoAnalytics, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA
1 shared publication Oscar Lopez
Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA
1 shared publication- Xiang-Qun Xie
Department of Pharmaceutical Sciences and Computational Chemical Genomics Screening Center, Pharmacometrics & Systems Pharmacology (PSP) PharmacoAnalytics, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA
1 shared publication
Latest Publications
- 25 August 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 107 (3) , 1294-1303
Impact of antidiabetic therapy on cognitive function in patients with type 2 diabetes and Alzheimer's disease: A comprehensive analysis
Background: Several hypotheses suggest that type 2 diabetes mellitus (T2DM) is a risk factor for Alzheimer's disease (AD), and antidiabetic medications may influence cognitive function in these patients. Objective: This study aims to provide a comprehensive evaluation of the impact of single and combination antidiabetic therapies on cognitive function in patients with both AD and T2DM. Methods: We analyzed data from the National Alzheimer's Coordinating Center (NACC), covering a 17-year period from June 2005 to August 2022. This study included 3234 patients with both AD and T2DM. After applying exclusion criteria, 964 patients were analyzed using propensity score matching and a generalized linear mixed model. Patients were categorized based on their longitudinal use of oral antidiabetic medications. Results: Based on the 964 patients’ cohort, the study found that patients receiving metformin with sulfonylureas (RR = 1.105 [1.022, 1.195], p = 0.013) and metformin with a dipeptidyl peptidase 4 inhibitor (DPP-4i) (RR = 1.132 [1.021, 1.256], p = 0.019) experienced a significantly slower decline in MMSE scores over time when compared to patients receiving metformin with thiazolidinediones (TZD). Conclusions: This study demonstrates that combination therapies involving metformin with sulfonylureas or DPP-4i are associated with a slower rate of cognitive decline compared to metformin with TZD in patients with AD and T2DM. These findings provide novel evidence for the long-term cognitive benefits of specific antidiabetic therapies and offer valuable insights for clinical decision-making in this dual-affected population.
- 25 August 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 107 (3) , 1294-1303
Impact of antidiabetic therapy on cognitive function in patients with type 2 diabetes and Alzheimer's disease: A comprehensive analysis
Background: Several hypotheses suggest that type 2 diabetes mellitus (T2DM) is a risk factor for Alzheimer's disease (AD), and antidiabetic medications may influence cognitive function in these patients. Objective: This study aims to provide a comprehensive evaluation of the impact of single and combination antidiabetic therapies on cognitive function in patients with both AD and T2DM. Methods: We analyzed data from the National Alzheimer's Coordinating Center (NACC), covering a 17-year period from June 2005 to August 2022. This study included 3234 patients with both AD and T2DM. After applying exclusion criteria, 964 patients were analyzed using propensity score matching and a generalized linear mixed model. Patients were categorized based on their longitudinal use of oral antidiabetic medications. Results: Based on the 964 patients’ cohort, the study found that patients receiving metformin with sulfonylureas (RR = 1.105 [1.022, 1.195], p = 0.013) and metformin with a dipeptidyl peptidase 4 inhibitor (DPP-4i) (RR = 1.132 [1.021, 1.256], p = 0.019) experienced a significantly slower decline in MMSE scores over time when compared to patients receiving metformin with thiazolidinediones (TZD). Conclusions: This study demonstrates that combination therapies involving metformin with sulfonylureas or DPP-4i are associated with a slower rate of cognitive decline compared to metformin with TZD in patients with AD and T2DM. These findings provide novel evidence for the long-term cognitive benefits of specific antidiabetic therapies and offer valuable insights for clinical decision-making in this dual-affected population.